Business
CSL to manufacture 81m COVID-19 vaccine doses by mid-2021 – The Australian Financial Review
CSL has secured agreements with AstraZeneca to produce 30 million doses of its vaccine candidate locally if the drug is successful.
The two deals are expected to cost the government more than $1.7 billion, if the vaccines become available.
At this stage the AstraZeneca vaccine is more advanced and is considered the leading candidate globally, with phase-three clinical trials already starting. The first doses are scheduled for release early next year. The UQ vaccine is expected to be ready a short time later in mid-2021.
CSL chief scientific officer Dr Andrew Nash was optimistic about the potential for a vaccine in early 2…
-
Noosa News21 hours agoHow Lily Steele-Park took her rapist to court and won
-
Business24 hours ago5 things to watch on the ASX 200 on Tuesday 8 July 2025
-
Noosa News22 hours agoE-biker charged with riding dangerously, assaulting cop
-
Business15 hours agoWhy Vault Minerals, Droneshield, Westgold Resources shares are climbing higher today